Latest / Moving Medicine Forward
Chill, Not Kill: How Quell Therapeutics is Reimagining Cell Therapy
In this episode of Moving Medicine Forward, Jeremy Schrand is joined by Luke Devey, Chief Medical Officer at Quell Therapeutics, and Savannah Doliboa, Chief Commercial Officer at CTI, to discuss how engineered regulatory T cell therapies are being developed to “chill, not kill” the immune system. The conversation explores Quell Therapeutics’ approach to Treg cell therapy, the complexity of launching advanced cell therapy trials across Europe, and how strong collaboration helped accelerate study startup for patients with serious autoimmune diseases.
00:00 Introduction to Quell Therapeutics and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.